Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Trends

Report ID: GMI5864
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

GLP-1 Receptor Agonist Market Trends

The market is expected to witness strong growth through 2032, driven by increasing interest in drugs with multiple administration routes and improved drug efficacy. New GLP-1 receptor agonist formulations, such as once-weekly injectable and oral versions, are gaining traction, improving patient compliance and market reach. Additionally, advancements in research have enabled the use of GLP-1 receptor agonists for obesity treatment, which is anticipated to expand their usage beyond diabetes management.

For instance, in October 2024, a retrospective cohort study indicated that women with type 2 diabetes who used GLP-1 receptor agonists had a lower risk of developing new-onset uterine fibroids compared to those taking other antidiabetic drugs. GLP-1 receptor agonists were associated with a significantly reduced risk of new fibroid onset compared to metformin, specifically among patients who received at least two doses of medication.

As the healthcare industry adapts to the evolving needs of diabetic and obese patients, the demand for GLP-1 receptor agonists that offer a range of therapeutic options and flexible dosing schedules is expected to drive market growth further.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global GLP-1 receptor agonist industry was valued at USD 24.4 billion in 2023 and is expected to grow at a 9.7% CAGR from 2024 to 2032, driven by rising incidences of type 2 diabetes and obesity globally.

he semaglutide segment held a dominant market share in 2023 and is projected to sustain growth through 2032 due to its efficacy in controlling blood sugar levels and promoting weight loss.

North America held the largest share of the GLP-1 receptor agonist market in 2022 and is projected to grow at a robust CAGR through 2032, driven by a high prevalence of diabetes, increasing obesity rates, and a well-established healthcare infrastructure.

Key players in the market include Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., and PegBio Co., Ltd.